GlaxoSmithKline has announced the completion of the divestment of travel vaccines Rabipur (tradename Rabavert in the US) for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic.
Consistent with the terms of the agreement first announced on October 21st 2019, GSK has received an upfront payment of EUR308 million (£263m), and in due course will receive further milestone payments for a total consideration of up to EUR955 million.
The decision to divest these brands supports GSK’s strategic intent to increase focus and reinvest in growth assets, innovation and a simplified supply chain in its vaccines business.
Rabipur is a well-established life-saving vaccine (rabies virus causes acute invariable fatal disease) with 30 years of market experience supported by extensive clinical and safety evidence and WHO pre-qualification. It is indicated both in persons bitten by suspect animals (PEP) and non-immune subjects at risk of rabies (PrEP).
Encepur is indicated for active immunization of high-risk populations against tick-borne encephalitis (TBE). It has unique dosing flexibility supported by proven efficacy and long-term persistence data.
